Securities Times e Company News, on May 24, Yunhe Pharmaceutical (Tianjin) Co., Ltd.(referred to as "Yunhe Pharmaceutical"), a wholly-owned subsidiary of Yunnan Baiyao (000538)pocketpokerThe Phase I/IIa clinical trial of the innovative nuclear drug INR101 injection completed the enrollment and administration of the first healthy subject at the Beijing Friendship Hospital Affiliated to Capital Medical University. INR101 injection is an innovative chemical Class 1 radiologic diagnostic drug developed by Yunhe Pharmaceutical. It is suitable for PET imaging of PSMA positive lesions in prostate cancer patients.
